Effectiveness and safety of rivaroxaban vs warfarin in patients with pulmonary embolism and right ventricular dysfunction: a retrospective cohort study

Figures

• 

  Figure 1. Study design. Data source: Mass General Brigham Research Patient Data Registry, January 2013 to May 2023. NLP, natural language processing; PE, pulmonary embolism; RVD, right ventricular dysfunction; VTE, venous thromboembolism. aOnly 15 mg and 20 mg prescriptions were considered for identifying rivaroxaban initiation. bDiscontinuation was defined as the last prescription of the index agent plus the median gap between prescriptions (ie, 64 and 33 days for rivaroxaban and warfarin, respectively). cObservation was censored at the time of active cancer, which was identified by the presence of both cancer diagnosis and treatment (at the later of the 2 dates). dDiagnosis of PE was identified in any position using the following diagnosis codes: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM): 415.1x; International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM): I26.0x, I26.90, I26.92, and I26.99. Among the study population, >96% of patients in each cohort had a primary diagnosis of PE or a secondary diagnosis of PE combined with an admission diagnosis of PE or a PE-related procedure during the index PE…

• 

  Figure 2. Kaplan–Meier venous thromboembolism (VTE) recurrence rates. CI, confidence interval. aThe number of patients still observed at the specific point in time, with no evidence of VTE. bVTE recurrence was defined as having ≥1 primary diagnosis of VTE in an inpatient setting during the on-treatment period.

• 

  Figure 3. Kaplan–Meier major bleeding rates. CI, confidence interval. aThe number of patients still observed at the specific point in time, with no evidence of venous thromboembolism. bMajor bleeding was identified using the Cunningham algorithm [11].